QIAGEN N.V.'s (QGEN) second-quarter 2024 adjusted earnings per share (EPS) were 55 cents, the same at the constant exchange rate (CER). The reported figure increased 7.8% from the 2023 comparable figure and topped the Zacks Consensus Estimate by 5.8%. The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others. On a GAAP basis, the lo ...

For the quarter ended June 2024, Qiagen (QGEN) reported revenue of $496.35 million, up 0.3% over the same period last year. EPS came in at $0.55, compared to $0.53 in the year-ago quarter. The reported revenue represents a surprise of +0.45% over the Zacks Consensus Estimate of $494.13 million. With the consensus EPS estimate being $0.52, the EPS surprise was +5.77%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.77%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of 4.55%. Over the last four quarters, the ...

Venlo, the Netherlands, July 31, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced results for the second quarter and first half of 2024. Net sales were stable at $496 million in Q2 2024 compared to Q2 2023, while results at constant exchanges rates (CER) of $502 million rose 1% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose about one percentage point to 28.4% from Q2 2023 on efficiency gains while supportin ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Qiagen (QGEN) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estima ...

QIAGEN N.V. (QGEN) is poised to grow in the upcoming quarters, backed by its robust progress in expanding the test menu options. The company's expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. In addition, sound financial stability instills optimism. In the past year, this Zacks Rank #2 (Buy) stock has declined 10.4% compared with a 4% decrease in the industry. The S&P 500 composite has witnessed a 23.4% rise in the said time frame. Let's delve deeper. Progress in T ...

Qiagen (QGEN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Most Powerful Force Impacting Stock Prices As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where t ...

QIAGEN N.V. (QGEN) recently announced a collaboration with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics. Under the partnership, Snow Molecular Anthropology Lab will have access to QIAGEN's MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System. The partnership should help QIAGEN maintain a leading position in the use of next-generation sequencing for forensic applications and human id ...

Missoula, Montana, and Venlo, the Netherlands, July 08, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics. Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System. "Our collaboration with ...

Press release date / time: Wednesday, July 31, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2492 Conference ID: 8081810 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. About QIAGEN Conference call date / time: Thursday, August 1, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Access the audio webcast - Click here: Access Webcast ...